{"id":54925,"date":"2023-03-16T18:05:43","date_gmt":"2023-03-16T17:05:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/"},"modified":"2023-03-16T18:05:43","modified_gmt":"2023-03-16T17:05:43","slug":"transgene-2022-full-year-results-and-business-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/","title":{"rendered":"Transgene: 2022 Full-year Results and Business Update"},"content":{"rendered":"
\n

\nPositive data on key clinical candidates delivered in 2022 \u2013 Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum<\/b>\n<\/p>\n

<\/a><\/p>\n

\n– TG4050:<\/i> <\/i><\/b>New Phase I data confirm the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II trial in head and neck cancer, which purpose is to provide data for a potential registration.<\/i>\n<\/p>\n

\n– TG4001:<\/i> <\/i><\/b>Positive interim analysis supports continuation of the ongoing randomized Phase II clinical trial. Final results to be reported in 2024. Transgene is preparing for a registration targeting study.<\/i>\n<\/p>\n

\n– Oncolytic viruses:<\/i> <\/i><\/b>New clinical data confirm the potential for Invir.IO\u00ae oncolytic viruses to be given via intravenous administration. Launch of the new multi-armed TG6050 aimed at a major solid tumor indication.<\/i>\n<\/p>\n

\n– \u20ac26.8 million in cash and cash equivalents<\/i><\/b> as of December 31, 2022 <\/i>\u2013<\/b> Financial visibility until early 2024.<\/i>\n<\/p>\n

\nConference call in English scheduled today at 6:00 p.m. CET (details at the end of the release)<\/i>\n<\/p>\n

STRASBOURG, France–(BUSINESS WIRE)–#HBV<\/a>–Regulatory News:\n<\/p>\n

\nTransgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer,<\/b> today publishes its financial results for 2022 and provides an update on its product pipeline.\n<\/p>\n

\nHedi Ben Brahim, CEO of Transgene<\/b>, commented: <\/b>\u201cI am extremely happy with the multiple positive milestones that Transgene has delivered in 2022 and I would like to thank all our employees and partners for their commitment and support. We also are very encouraged by the growing industry interest in therapeutic cancer vaccines and oncolytic viruses that have the potential to become new standards of care for the treatment of solid tumors. This trend backs us in our strategy and validates our technological and medical choices. I am confident that Transgene is at the forefront of helping to realize the potential of these exciting treatment modalities.<\/i>\n<\/p>\n

\n\u201cWith regard to our therapeutic cancer vaccine pipeline, we presented new Phase I results for TG4050 demonstrating the full clinical and commercial potential of this highly innovative neoantigen vaccine in patients with head and neck cancer. These very encouraging data have led us to start the planning of Phase II trial. Positive data from this Phase II trial could be used for a potential registration of TG4050. For TG4001, our most advanced product, the positive outcome of the interim analysis of the Phase II trial in HPV-positive cancers has allowed us to reduce the total number of patients to be randomized in the ongoing study.<\/i>\n<\/p>\n

\n\u201cTurning to the oncolytic virus platform, we have achieved two important milestones. We presented new positive data from the Phase I trial evaluating our oncolytic virus TG6002 administered intravenously, showing in all patients its ability to reach the tumor, multiply and express its payload. The ability to administer our oncolytic viruses intravenously significantly expands the range of solid tumors they can be used to treat and the market opportunity they can access. In addition, we announced the launch of a new oncolytic virus, TG6050. This multi-armed oncolytic virus has been designed to address major solid tumor indications, such as lung cancer, and will begin a Phase I in the months ahead.<\/i>\n<\/p>\n

\n\u201cThe progress we have made in 2022 has positioned Transgene to deliver multiple major milestones in the next 18 months, including launching potentially registrational trials for our two most advanced therapeutic vaccine candidates, as well as a Phase I study with our high-potential oncolytic virus, TG6050, given by intravenous administration.<\/i>\n<\/p>\n

\n\u201cBased on the potential of TG4050, TG4001 and TG6050, I believe that Transgene has a very exciting future and is well positioned to deliver for all of its key stakeholders.<\/i>\u201d\n<\/p>\n

\nKey achievements in 2022 and expected near-term news flow\n<\/p>\n

\nTherapeutic Cancer Vaccines<\/b>\n<\/p>\n

\nTG4001: Positive result from interim analysis of randomized Phase II trial in HPV-positive anogenital cancers\n<\/p>\n

\nWith TG4001, Transgene aims to bring a new solution to patients with HPV-positive anogenital cancers who currently have very limited second-line treatment options.\n<\/p>\n

\nIn November 2022, Transgene announced that following a prespecified interim analysis of its randomized, Phase II clinical study comparing TG4001 in combination with avelumab vs avelumab alone in patients with HPV16-positive anogenital tumors <\/b>(NCT: 03260023<\/a>), the Independent Data Monitoring Committee (IDMC) has recommended the study continue<\/b>. Based on progression-free survival (PFS) and positive efficacy signals <\/b>observed in the interim analysis, the trial is now expected to enroll a total of 120 patients<\/b> compared to the initial forecast of 150 patients.\n<\/p>\n

\nTransgene anticipates the last patient to be randomized in the trial in the first half of 2024, and final results to be communicated in 2024.<\/b>\n<\/p>\n

\nBased on the positive outcome of the interim analysis, <\/b>we <\/b>are already working on the initial design of a potentially registrational trial to further confirm the benefit of this therapeutic vaccine.\n<\/p>\n

\nTG4050: Strong clinical and commercial potential confirmed by initial data from the two ongoing Phase I trials \u2013 Transgene is preparing a Phase II trial in head and neck cancers\n<\/p>\n

\nThe personalized therapeutic vaccine TG4050 is intended to extend the remission of patients at high risk of relapse.\n<\/p>\n

\nIn the randomized Phase I trial in head and neck patients, following surgery and radio-chemotherapy, <\/b>the latest data reported was as of the end of August 2022, when 20 of the 30 planned patients had been randomized.<\/b>\n<\/p>\n

\nAll 10 evaluable patients who were vaccinated with TG4050 remained stable and in complete response <\/b>at the cutoff date. This contrasts with the control group where 2 out of the 10 patients, who did not receive the vaccine, have relapsed.<\/b> Transgene expects treatment start of the last patient in this Phase I trial in the first half of 2023.\n<\/p>\n

\nIn the current Phase I ovarian cancer trial (n=5), <\/b>one patient treated after an elevation of CA-125 experienced a normalization of CA-125 without clinical progression for nine months until death from an unrelated chronic illness. Another patient was treated upon onset of radiological evidence of relapse and remained stable for 11.4 months. Although enrollment in this trial has been completed, treatment of patients is significantly delayed by the recent registration of PARP inhibitors, extending the time to relapse, which is required before they can receive treatment with TG4050.\n<\/p>\n

\nTransgene has also produced data on circulating tumor DNA (ctDNA); signals of this increasingly validated surrogate marker of efficacy are particularly encouraging. Combined with the first signs of clinical activity, these results suggest that the individualized TG4050 vaccine has the potential to extend the period of remission, potentially offering a new treatment option for cancer patients.<\/b>\n<\/p>\n

\nIn the two clinical studies, enrollment has been completed. To date, TG4050 vaccine has been well tolerated and no related Serious Adverse Events have been reported.<\/b>\n<\/p>\n

\nThe Company is preparing a Phase II trial in head and neck cancers.<\/b> Positive data from this upcoming trial could be used for a potential registration of TG4050.\n<\/p>\n

\nFurther information on our development plans for TG4050 will be communicated following the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting (April 2023).<\/b>\n<\/p>\n

\nOncolytic Viruses<\/b>\n<\/p>\n

\nTG6002: New data support the potential of intravenous administration of Invir.IO\u00ae-based oncolytic viruses \u2013<\/b> Key competitive advantage\n<\/p>\n

\nClinical data generated with TG6002, has enabled Transgene to confirm the mechanism of action, competitive advantages and safety of our Invir.IO\u00ae based oncolytic viruses.\n<\/p>\n

\nData generated on 37 patients treated in the Phase I study assessing its intravenous administration (IV) have been presented at the European Society for Medical Oncology (ESMO) Annual Congress (September 2022).\n<\/p>\n

\nThese findings support the potential of IV administration of Invir.IO\u00ae-based oncolytic viruses, extending the use of these therapies to a much broader range of solid tumors. At present the use of oncolytic viruses is limited by their intratumoral administration.<\/b>\n<\/p>\n

\nAdditional data will be produced from the Phase I program and will be presented at AACR (April 2023).\n<\/p>\n

\nBT-001: Positive initial clinical data in monotherapy\n<\/p>\n

\nIn June 2022, Transgene and BioInvent released positive progress and safety data in the ongoing Phase I\/IIa trial evaluating BT-001 in patients with solid tumors.<\/b> The initial data generated in the Part A of the Phase I trial demonstrated that BT-001 alone is well tolerated, with first signs of anti-tumor activity in a hard-to-treat population and confirmed the mechanism of action of BT-001 as a single agent.\n<\/p>\n

\nA clinical collaboration and supply agreement for KEYTRUDA\u00ae (pembrolizumab) was signed with MSD (Merck & Co) at the end of June 2022. The Part B of the Phase I trial (in combination with pembrolizumab) is expected to start in the second half of 2023.\n<\/p>\n

\nTG6050: Novel Invir.IO\u00ae candidate designed to express IL-12 and be administered IV to enter the clinic\n<\/p>\n

\nIn early 2023, Transgene announced the regulatory approval to initiate a clinical trial of TG6050, a novel oncolytic virus from its Invir.IO\u00ae platform. This innovative candidate has been designed to express human IL-12, a cytokine known to trigger a potent anti-tumor immune response, and a full-length anti-CTLA4 antibody.\n<\/p>\n

\nThe Delivir trial will evaluate TG6050 in patients with advanced non-small cell lung cancer who have failed treatment with an anti-PD1 agent.\n<\/p>\n

\nThe first patient will be enrolled in the first half of 2023. With TG6050, Transgene seeks to capitalize on the attractiveness of IL-12, while limiting exposure to its systemic toxicity through the selectivity of Invir.IO\u00ae oncolytic viruses.\n<\/p>\n

\nCollaboration with AstraZeneca\n<\/p>\n

\nThe research collaboration with AstraZeneca on viruses derived from the Invir.IO\u00ae platform continues to move forward.\n<\/p>\n

\nKey scientific advisors\n<\/p>\n

\nIn March 2023, Transgene appointed Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors. These key opinion leaders in cancer immunotherapy bring considerable expertise to Transgene.\n<\/p>\n

\nSummary of key ongoing clinical trials\n<\/p>\n\n\n
\n

\nTG4001<\/b>\n<\/p>\n

\n+ avelumab<\/b>
Phase II\n<\/p>\n

\nNCT03260023\n<\/p>\n<\/td>\n

\n

\nTargets: HPV16 E6 and E7 oncoproteins<\/b>\n<\/p>\n

\nRecurrent\/metastatic anogenital HPV16-positive \u2014 1st<\/sup> (patients ineligible for chemotherapy) and 2nd<\/sup> lines<\/span><\/i>\n<\/p>\n

\n\u2713 Randomized Phase II trial comparing the combination of TG4001 with avelumab versus avelumab alone\n<\/p>\n

\n\u2713 Ongoing patient enrollment in Europe (France and Spain) and in the USA\n<\/p>\n

\n\u2713 Positive result of interim analysis, allowing trial to continue. Total number of patients to be randomized reduced from 150 to 120\n<\/p>\n

\n\u27b2 Last patient expected to be randomized in H1 2024<\/b>\n<\/p>\n

\n\u27b2 Final results to be communicated in 2024<\/b>\n<\/p>\n

\n\u27b2 Registration targeting trial being prepared<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n
\n

\nmyvac\u00ae<\/i>\n<\/p>\n

\n\u00a0\n<\/p>\n

\n\u00a0\n<\/p>\n

\n\u00a0\n<\/p>\n

\n\u00a0\n<\/p>\n

\nTG4050<\/b>\n<\/p>\n

\nPhase I\n<\/p>\n

\nNCT04183166\n<\/p>\n<\/td>\n

\n

\nTargets<\/b>: tumor<\/b> neoantigens<\/b>\n<\/p>\n

\n\u2713 Codeveloped with NEC\n<\/p>\n

\n\u2713 Positive initial data demonstrating the immunogenicity of the vaccine as well as first signs of clinical activity\n<\/p>\n

\n\u27b2 Additional data expected in H1 2023 (AACR)<\/b>\n<\/p>\n

\nHPV-negative head and neck cancers \u2014 after surgery and adjuvant therapy<\/span><\/i>\n<\/p>\n

\n\u2713 Trial ongoing in the UK and in France\n<\/p>\n

\n\u2713 Patient enrollment completed\n<\/p>\n

\n\u2713 Treatment start of last patient expected in H1 2023\n<\/p>\n

\n\u27b2 Preparation of registration targeting Phase II trial<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTG4050<\/b>\n<\/p>\n

\nPhase I\n<\/p>\n

\nNCT03839524\n<\/p>\n<\/td>\n

\n

\nOvarian cancer \u2014 after surgery and first-line chemotherapy<\/span><\/i>\n<\/p>\n

\n\u2713 Trial ongoing in the USA and in France\n<\/p>\n

\n\u2713 Patient enrollment completed\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n
\n

\nTG6002<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\n\u00a0\n<\/p>\n

\nPhase I\/IIa\n<\/p>\n

\nNCT03724071\n<\/p>\n<\/td>\n

\n

\nPayload: FCU1 for the local production of a 5-FU chemotherapy<\/b>\n<\/p>\n

\n\u27b2 Additional data to be presented at AACR (April 2023)<\/b>\n<\/p>\n

\nAdvanced gastro-intestinal cancer \u2014 Intravenous (IV) administration<\/span><\/i>\n<\/p>\n

\n\u2713 Multicenter trial \u2013<\/b> France, Belgium and Spain\n<\/p>\n

\n\u2713 Data confirming the potential of the IV administration presented at ESMO 2022 (Sept. 2022)<\/b>\n<\/p>\n

\n\u2713 Patient enrollment completed in Phase I part\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTG6002<\/b>\n<\/p>\n

\nPhase I\/IIa\n<\/p>\n

\nNCT04194034\n<\/p>\n<\/td>\n

\n

\nColorectal cancer with liver metastasis \u2014 Intrahepatic artery (IHA) administration<\/span><\/i>\n<\/p>\n

\n\u2713 Multicenter trial \u2013<\/b> UK and France\n<\/p>\n

\n\u2713 Patient enrollment completed in Phase I part\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n
\n

\nInvir.IO\u00ae\n<\/p>\n

\nBT-001<\/b>\n<\/p>\n

\nPhase I\/IIa\n<\/p>\n

\n\u00a0\n<\/p>\n

\nNCT04725331\n<\/p>\n<\/td>\n

\n

\nPayload: anti-CTLA4 antibody and GM-CSF cytokine<\/b>\n<\/p>\n

\nSolid tumors<\/span><\/i>\n<\/p>\n

\n\u2713 Co-development with BioInvent\n<\/p>\n

\n\u2713 Collaboration agreement with MSD, supplying pembrolizumab for the trial\n<\/p>\n

\n\u2713 Trial ongoing in France, Belgium and approved in the USA\n<\/p>\n

\n\u2713 Initial data showing safety and first signs of clinical activity\n<\/p>\n

\n\u27b2 Part A data to be communicated in H1 2023<\/b>\n<\/p>\n

\n\u27b2 Start of part B of the Phase I trial in H2 2023<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n
\n

\nInvir.IO\u00ae\n<\/p>\n

\nTG6050<\/b>\n<\/p>\n

\nPhase I (Delivir)\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nPayload: interleukin-12 (IL-12) and anti-CTLA4 antibody<\/b>\n<\/p>\n

\nNon-Small Cell Lung Cancer (NSCLC) \u2013 Intravenous (IV) administration<\/span><\/i>\n<\/p>\n

\n\u2713 Promising preclinical results to be presented at AACR (April 2023)\n<\/p>\n

\n\u2713 Multicenter trial\n<\/p>\n

\n\u27b2 First patient to be enrolled in H1 2023<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nKey financials for 2022\n<\/p>\n

\n– Operating income of \u20ac10.3 million in 2022<\/b>, compared to \u20ac17.4 million in 2021.\n<\/p>\n

\nR&D services for third parties amounted to \u20ac3.1 million in 2022 (\u20ac10.0 million in 2021), mainly due to the collaboration with AstraZeneca. In 2021, AstraZeneca exercised the first license option for an oncolytic virus developed by Transgene. This option exercise led to Transgene receiving a \u20ac7.1 million payment.\n<\/p>\n

\nResearch tax credit amounted to \u20ac6.8 million in 2022 (\u20ac7.0 million in 2021).\n<\/p>\n

\n– Net operating expenses of \u20ac40.2 million in 2022, <\/b>compared to \u20ac40.9 million in 2021.\n<\/p>\n

\nR&D expenses were \u20ac32.2 million in 2022 (\u20ac32.9 million in 2021).\n<\/p>\n

\nGeneral and administrative expenses amounted to \u20ac7.9 million in 2022 (\u20ac7.4 million in 2021).\n<\/p>\n

\n– Financial loss of \u20ac2.9 million in 2022<\/b>, compared to an income of \u20ac4.0 million in 2021.\n<\/p>\n

\n– Net loss of \u20ac32.8 million in 2022, <\/b>compared to a net loss of \u20ac19.5 million in 2021.\n<\/p>\n

\n– Net cash burn of \u20ac22.8 million in 2022, <\/b>compared to \u20ac10.0 million in 2021 (excluding capital increase).\n<\/p>\n

\n– Cash available at year-end 2022: \u20ac26.8 million<\/b>, compared to \u20ac49.6 million at the end of 2021. In addition, Transgene still holds Tasly BioPharmaceuticals shares reevaluated at \u20ac14.3 million at the end of December 2022. The Company is expecting to sell its shareholding in Tasly BioPharmaceuticals in mid-2023.\n<\/p>\n

\n– Transgene has a financial visibility until early 2024.<\/b>\n<\/p>\n

\nThe financial statements for 2022 as well as management\u2019s discussion and analysis are attached to this press release (Appendices A and B).\n<\/p>\n

\nThe Board of Directors of Transgene met on March 16, 2023, under the chairmanship of Dr. Alessandro Riva and closed the 2022 financial statements. Audit procedures have been performed by the statutory auditors and the delivery of the auditors\u2019 report is ongoing.<\/i>\n<\/p>\n

\nThe Company\u2019s universal registration document, which includes the annual financial report, will be available early April 2023 on Transgene\u2019s website, <\/i>www.transgene.fr<\/i><\/a>.<\/i>\n<\/p>\n

\nA conference call in English<\/b> is scheduled today on March 16, 2023, at 6:00 p.m. CET (12:00 p.m. ET)<\/b>.\n<\/p>\n

\nWebcast link to English language conference call: <\/i><\/b>https:\/\/channel.royalcast.com\/landingpage\/transgene\/20230316_1\/<\/a>\n<\/p>\n

\nParticipant telephone numbers:<\/i><\/b>\n<\/p>\n\n\n
\n

\nFrance: +33 (0) 1 7037 7166\n<\/p>\n

\nUnited Kingdom: +44 (0) 33 0551 0200\n<\/p>\n

\nUnited States: +1 786 697 3501\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nConfirmation code: Transgene\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nA replay of the call will be available on the Transgene website (www.transgene.fr<\/a><\/span>) following the live event.\n<\/p>\n

\n***\n<\/p>\n

\nAbout Transgene<\/i><\/b>\n<\/p>\n

\nTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.\n<\/p>\n

\nThe Company\u2019s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses:\n<\/p>\n

\nTG4050, the first individualized therapeutic vaccine based on the myvac<\/i>\u00ae platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO\u00ae viral backbone.\n<\/p>\n

\nWith Transgene\u2019s myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.\n<\/p>\n

\nWith its proprietary platform Invir.IO\u00ae, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u00ae collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr<\/a>\n<\/p>\n

\nFollow us on Twitter: @TransgeneSA<\/a>\n<\/p>\n

\nDisclaimer<\/i><\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i>\n<\/p>\n

\nAppendix A: Financial statements 2022<\/span><\/b>\n<\/p>\n

\nCONSOLIDATED BALANCE SHEET, IFRS
\n
<\/b>(in \u20ac thousands)<\/i>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nAssets<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2022<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCURRENT ASSETS<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash and cash equivalents\n<\/p>\n<\/td>\n

\n

\n4,403\n<\/p>\n<\/td>\n

\n

\n5,911\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current financial assets\n<\/p>\n<\/td>\n

\n

\n22,423\n<\/p>\n<\/td>\n

\n

\n43,658\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash, cash equivalents and other current financial assets<\/b>\n<\/p>\n<\/td>\n

\n

\n26,826<\/b>\n<\/p>\n<\/td>\n

\n

\n49,569<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTrade receivables\n<\/p>\n<\/td>\n

\n

\n2,789\n<\/p>\n<\/td>\n

\n

\n10,133\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current assets\n<\/p>\n<\/td>\n

\n

\n2,546\n<\/p>\n<\/td>\n

\n

\n2,543\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAssets available for sale\n<\/p>\n<\/td>\n

\n

\n14,345\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal current assets<\/b>\n<\/p>\n<\/td>\n

\n

\n46,506<\/b>\n<\/p>\n<\/td>\n

\n

\n62,245<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNON-CURRENT ASSETS<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nProperty, plant and equipment\n<\/p>\n<\/td>\n

\n

\n11,177\n<\/p>\n<\/td>\n

\n

\n11,295\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIntangible assets\n<\/p>\n<\/td>\n

\n

\n77\n<\/p>\n<\/td>\n

\n

\n92\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNon-current financial assets\n<\/p>\n<\/td>\n

\n

\n1,673\n<\/p>\n<\/td>\n

\n

\n20,772\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther non-current assets\n<\/p>\n<\/td>\n

\n

\n7,003\n<\/p>\n<\/td>\n

\n

\n7,434\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal non-current assets<\/b>\n<\/p>\n<\/td>\n

\n

\n19,930<\/b>\n<\/p>\n<\/td>\n

\n

\n39,593<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTOTAL ASSETS<\/b>\n<\/p>\n<\/td>\n

\n

\n66,436<\/b>\n<\/p>\n<\/td>\n

\n

\n101,838<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nLiabilities and equity<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2022<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCURRENT LIABILITIES<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTrade payables\n<\/p>\n<\/td>\n

\n

\n6,965\n<\/p>\n<\/td>\n

\n

\n7,692\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCurrent financial liabilities\n<\/p>\n<\/td>\n

\n

\n1,192\n<\/p>\n<\/td>\n

\n

\n1,395\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nProvisions for risks and expenses\n<\/p>\n<\/td>\n

\n

\n23\n<\/p>\n<\/td>\n

\n

\n48\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current liabilities\n<\/p>\n<\/td>\n

\n

\n4,602\n<\/p>\n<\/td>\n

\n

\n5,454\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal current liabilities<\/b>\n<\/p>\n<\/td>\n

\n

\n12,782<\/b>\n<\/p>\n<\/td>\n

\n

\n14,589<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNON-CURRENT LIABILITIES<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNon-current financial liabilities\n<\/p>\n<\/td>\n

\n

\n12,327\n<\/p>\n<\/td>\n

\n

\n15,241\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEmployee benefits\n<\/p>\n<\/td>\n

\n

\n3,282\n<\/p>\n<\/td>\n

\n

\n3,958\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther non-current liabilities\n<\/p>\n<\/td>\n

\n

\n204\n<\/p>\n<\/td>\n

\n

\n841\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal non-current liabilities<\/b>\n<\/p>\n<\/td>\n

\n

\n15,813<\/b>\n<\/p>\n<\/td>\n

\n

\n20,040<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal liabilities<\/b>\n<\/p>\n<\/td>\n

\n

\n28,595<\/b>\n<\/p>\n<\/td>\n

\n

\n34,629<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEQUITY<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare capital\n<\/p>\n<\/td>\n

\n

\n50,102\n<\/p>\n<\/td>\n

\n

\n48,886\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare premiums and reserves\n<\/p>\n<\/td>\n

\n

\n71,621\n<\/p>\n<\/td>\n

\n

\n70,374\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRetained earnings\n<\/p>\n<\/td>\n

\n

\n(50,628)\n<\/p>\n<\/td>\n

\n

\n(31,092)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nProfit\/(loss) for the period\n<\/p>\n<\/td>\n

\n

\n(32,804)\n<\/p>\n<\/td>\n

\n

\n(19,536)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther comprehensive income\/(loss)\n<\/p>\n<\/td>\n

\n

\n(450)\n<\/p>\n<\/td>\n

\n

\n(1,423)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal equity attributable to the Company\u2019s shareholders<\/b>\n<\/p>\n<\/td>\n

\n

\n37,841<\/b>\n<\/p>\n<\/td>\n

\n

\n67,209<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTOTAL LIABILITIES AND EQUITY<\/b>\n<\/p>\n<\/td>\n

\n

\n66,436<\/b>\n<\/p>\n<\/td>\n

\n

\n101,838<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nConsolidated income statement, IFRS
\n
<\/b>(in \u20ac thousands, except for per-share data)<\/i>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nDecember 31,2022<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRevenue from collaborative and licensing agreements\n<\/p>\n<\/td>\n

\n

\n3,126\n<\/p>\n<\/td>\n

\n

\n9,993\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGovernment financing for research expenditure\n<\/p>\n<\/td>\n

\n

\n6,876\n<\/p>\n<\/td>\n

\n

\n7,021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther income\n<\/p>\n<\/td>\n

\n

\n342\n<\/p>\n<\/td>\n

\n

\n399\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating income<\/b>\n<\/p>\n<\/td>\n

\n

\n10,344<\/b>\n<\/p>\n<\/td>\n

\n

\n17,413<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nResearch and development expenses\n<\/p>\n<\/td>\n

\n

\n(32,168)\n<\/p>\n<\/td>\n

\n

\n(32,883)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGeneral and administrative expenses\n<\/p>\n<\/td>\n

\n

\n(7,912)\n<\/p>\n<\/td>\n

\n

\n(7,369)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther expenses\n<\/p>\n<\/td>\n

\n

\n(168)\n<\/p>\n<\/td>\n

\n

\n(686)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses<\/b>\n<\/p>\n<\/td>\n

\n

\n(40,248)<\/b>\n<\/p>\n<\/td>\n

\n

\n(40,938)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating income\/(loss)<\/b>\n<\/p>\n<\/td>\n

\n

\n(29,904)<\/b>\n<\/p>\n<\/td>\n

\n

\n(23,525)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nFinancial income\/(loss)\n<\/p>\n<\/td>\n

\n

\n(2,900)\n<\/p>\n<\/td>\n

\n

\n3,989\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome\/(loss) before tax<\/b>\n<\/p>\n<\/td>\n

\n

\n(32,804)<\/b>\n<\/p>\n<\/td>\n

\n

\n(19,536)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome tax expense\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNET INCOME\/(LOSS)<\/b>\n<\/p>\n<\/td>\n

\n

\n(32,804)<\/b>\n<\/p>\n<\/td>\n

\n

\n(19,536)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBasic earnings per share (\u20ac)\n<\/p>\n<\/td>\n

\n

\n(0.33)\n<\/p>\n<\/td>\n

\n

\n(0.21)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDiluted earnings per share (\u20ac)\n<\/p>\n<\/td>\n

\n

\n(0.33)\n<\/p>\n<\/td>\n

\n

\n(0.21)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nCash Flow statement, IFRS<\/b>\n<\/p>\n

\n(in \u20ac thousands)<\/i>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nDecember 31,2022<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 31,2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash flow from operating activities<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet income\/(loss)\n<\/p>\n<\/td>\n

\n

\n(32,804)\n<\/p>\n<\/td>\n

\n

\n(19,536)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCancellation of financial income\/(loss)\n<\/p>\n<\/td>\n

\n

\n2,900\n<\/p>\n<\/td>\n

\n

\n(3,989)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nElimination of non-cash items<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nProvisions\n<\/p>\n<\/td>\n

\n

\n191\n<\/p>\n<\/td>\n

\n

\n(1,031)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDepreciation and amortization\n<\/p>\n<\/td>\n

\n

\n1,686\n<\/p>\n<\/td>\n

\n

\n2,521\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare-based payments\n<\/p>\n<\/td>\n

\n

\n2,675\n<\/p>\n<\/td>\n

\n

\n3,002\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOthers\n<\/p>\n<\/td>\n

\n

\n(41)\n<\/p>\n<\/td>\n

\n

\n(112)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet cash generated from\/(used in) operating activities before change in working capital and other operating cash flow<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

\n(25,393)<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

\n(19,145)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nChange in operating working capital requirements<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCurrent receivables and prepaid expenses\n<\/p>\n<\/td>\n

\n

\n7,301\n<\/p>\n<\/td>\n

\n

\n(7,745)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nResearch tax credit (RTC)\n<\/p>\n<\/td>\n

\n

\n(198)\n<\/p>\n<\/td>\n

\n

\n(993)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current assets\n<\/p>\n<\/td>\n

\n

\n226\n<\/p>\n<\/td>\n

\n

\n(242)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTrade payables\n<\/p>\n<\/td>\n

\n

\n(750)\n<\/p>\n<\/td>\n

\n

\n2,657\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPrepaid income\n<\/p>\n<\/td>\n

\n

\n(804)\n<\/p>\n<\/td>\n

\n

\n(1,124)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther current liabilities\n<\/p>\n<\/td>\n

\n

\n(685)\n<\/p>\n<\/td>\n

\n

\n683\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet cash used in operating activities<\/b>\n<\/p>\n<\/td>\n

\n

\n(20,303)<\/b>\n<\/p>\n<\/td>\n

\n

\n(25,909)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash flows from investing activities<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(Acquisitions)\/disposals of property, plant and equipment\n<\/p>\n<\/td>\n

\n

\n(1,497)\n<\/p>\n<\/td>\n

\n

\n(671)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(Acquisitions)\/disposals of intangible assets\n<\/p>\n<\/td>\n

\n

\n(38)\n<\/p>\n<\/td>\n

\n

\n(15)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(Acquisitions)\/disposals of non-consolidated equity securities\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n17,193\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(Acquisitions) of other financial assets\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n(40,000)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDisposals of other financial assets\n<\/p>\n<\/td>\n

\n

\n21,500\n<\/p>\n<\/td>\n

\n

\n17,418\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther (acquisitions)\/disposals\n<\/p>\n<\/td>\n

\n

\n307\n<\/p>\n<\/td>\n

\n

\n286\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet cash used in investing activities<\/b>\n<\/p>\n<\/td>\n

\n

\n20,272<\/b>\n<\/p>\n<\/td>\n

\n

\n(5,789)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash flow from financing activities<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet financial income\/(loss) proceeds\n<\/p>\n<\/td>\n

\n

\n(646)\n<\/p>\n<\/td>\n

\n

\n(167)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGross proceeds from the issuance of shares\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n34,129\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare issue costs\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n(787)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nConditional subsidies\n<\/p>\n<\/td>\n

\n

\n455\n<\/p>\n<\/td>\n

\n

\n603\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet amounts received for financing of tax credits\n<\/p>\n<\/td>\n

\n

\n(5)\n<\/p>\n<\/td>\n

\n

\n16\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBank borrowing\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n(197)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nFinancial leases and change in lease obligations\n<\/p>\n<\/td>\n

\n

\n(1,281)\n<\/p>\n<\/td>\n

\n

\n(1,277)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet cash generated from\/(used in) financing activities<\/b>\n<\/p>\n<\/td>\n

\n

\n(1,477)<\/b>\n<\/p>\n<\/td>\n

\n

\n32,320<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nExchange rate differences on cash and cash equivalents\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n12\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet increase\/(decrease) in cash and cash equivalents<\/b>\n<\/p>\n<\/td>\n

\n

\n(1,508)<\/b>\n<\/p>\n<\/td>\n

\n

\n634<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash and cash equivalents at beginning of period\n<\/p>\n<\/td>\n

\n

\n5,911\n<\/p>\n<\/td>\n

\n

\n5,277\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash and cash equivalents at end of period<\/b>\n<\/p>\n<\/td>\n

\n

\n4,403<\/b>\n<\/p>\n<\/td>\n

\n

\n5,911<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInvestments in other current financial assets\n<\/p>\n<\/td>\n

\n

\n22,423\n<\/p>\n<\/td>\n

\n

\n43,658\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCash, cash equivalent and other current financial assets<\/b>\n<\/p>\n<\/td>\n

\n

\n26,826<\/b>\n<\/p>\n<\/td>\n

\n

\n49,569<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAppendix B: Management Discussion of 2022 Financials<\/span><\/b>\n<\/p>\n

\nOperating income<\/b>\n<\/p>\n

\nIncome from collaboration and licensing agreements represented \u20ac3.1 million in 2022 versus \u20ac10.0 million in 2021. The income consisted primarily of research and development services recognized from the collaboration with AstraZeneca over the period amounting to \u20ac3.1 million in 2022 (versus \u20ac9.9 million in 2021). This difference is mainly due to the first license option exercised by AstraZeneca in 2021 for \u20ac7.1 million, for an oncolytic virus developed by Transgene.\n<\/p>\n

\nPublic funding for research expenses accounted for \u20ac6.9 million in 2022 (versus \u20ac7.0 million in 2021), mainly due to research tax credit.\n<\/p>\n

\nOther income<\/b>\n<\/p>\n

\nOther income amounted to \u20ac0.3 million in 2022 versus \u20ac0.4 million in 2021. This consisted for \u20ac0.2 million of the NEOVIVA repayable advances at a preferred rate in 2022, as in 2021.\n<\/p>\n

\nOperating expenses<\/b>\n<\/p>\n

\nResearch and development (R&D) expenses<\/i><\/b>\n<\/p>\n

\nR&D expenses amounted to \u20ac32.2 million in 2022 versus \u20ac32.9 million in 2021.\n<\/p>\n

\nThe following table details R&D expenses by type:\n<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\n(in \u20ac millions)<\/i>\n<\/p>\n<\/td>\n

\n

\nDec. 31, 2022<\/b>\n<\/p>\n<\/td>\n

\n

\nDec. 31, 2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPayroll costs\n<\/p>\n<\/td>\n

\n

\n12.2\n<\/p>\n<\/td>\n

\n

\n12.4\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare-based payments\n<\/p>\n<\/td>\n

\n

\n1.4\n<\/p>\n<\/td>\n

\n

\n1.7\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIntellectual property expenses and licensing costs\n<\/p>\n<\/td>\n

\n

\n1.1\n<\/p>\n<\/td>\n

\n

\n1.1\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nExternal expenses for clinical projects\n<\/p>\n<\/td>\n

\n

\n6.2\n<\/p>\n<\/td>\n

\n

\n6.3\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nExternal expenses for other projects\n<\/p>\n<\/td>\n

\n

\n4.3\n<\/p>\n<\/td>\n

\n

\n4.5\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses\n<\/p>\n<\/td>\n

\n

\n5.4\n<\/p>\n<\/td>\n

\n

\n5.1\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDepreciation, amortization and provisions\n<\/p>\n<\/td>\n

\n

\n1.6\n<\/p>\n<\/td>\n

\n

\n1.8\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRESEARCH AND DEVELOPMENT EXPENSES<\/b>\n<\/p>\n<\/td>\n

\n

\n32.2<\/b>\n<\/p>\n<\/td>\n

\n

\n32.9<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Contacts<\/b> <\/p>\n

\nTransgene:<\/b>
Lucie Larguier<\/b>
Director Corporate Communications & IR
\n
+33 (0)3 88 27 91 04
\n
investorrelations@transgene.fr<\/span><\/a>\n<\/p>\n

\nMedia: MEDiSTRAVA Consulting<\/b>
David Dible\/Sylvie Berrebi\/George Underwood<\/b>
+44 (0)203 928 6900
\n
transgene@medistrava.com<\/a>\n<\/p>\n

Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Positive data on key clinical candidates delivered in 2022 \u2013 Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum – TG4050: New Phase I data confirm the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II trial in head and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54925","6":"format-standard","7":"category-industry"},"yoast_head":"\nTransgene: 2022 Full-year Results and Business Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene: 2022 Full-year Results and Business Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Positive data on key clinical candidates delivered in 2022 \u2013 Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum – TG4050: New Phase I data confirm the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II trial in head and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T17:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transgene: 2022 Full-year Results and Business Update\",\"datePublished\":\"2023-03-16T17:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/\"},\"wordCount\":3281,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005582\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/\",\"name\":\"Transgene: 2022 Full-year Results and Business Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005582\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"datePublished\":\"2023-03-16T17:05:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005582\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005582\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-2022-full-year-results-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene: 2022 Full-year Results and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene: 2022 Full-year Results and Business Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Transgene: 2022 Full-year Results and Business Update - Pharma Trend","og_description":"Positive data on key clinical candidates delivered in 2022 \u2013 Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum – TG4050: New Phase I data confirm the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II trial in head and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-16T17:05:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transgene: 2022 Full-year Results and Business Update","datePublished":"2023-03-16T17:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/"},"wordCount":3281,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/","url":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/","name":"Transgene: 2022 Full-year Results and Business Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg","datePublished":"2023-03-16T17:05:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230316005582\/en\/1192643\/21\/Logo_Transgene.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transgene-2022-full-year-results-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transgene: 2022 Full-year Results and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54925"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54925\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}